Results 171 to 180 of about 7,935 (218)

The Future of Thiopurine Pharmacogenomics

Pharmacogenomics, 2012
Since their invention [1], thiopurines (azathioprine, 6-mercaptopurine [6MP], and 6-thioguanine [6TG]) have significantly advanced the treatment of acute lymphoblastic leukemia, organ transplantation, inflammatory bowel disease (IBD) and various autoimmune diseases.
Duley, John A., Somogyi, Andrew A., Martin, Jennifer H.   +2 more
openaire   +5 more sources

The Effect of Thiopurine Methyltransferase Expression on Sensitivity to Thiopurine Drugs

Molecular Pharmacology, 2002
Although the thiopurine drugs 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are well established agents for the treatment of leukemia, controversies remain regarding their main mode of action. Previous evidence has suggested that although 6-TG exerts a cytotoxic effect through incorporation of 6-thioguanine nucleotides into newly synthesized DNA ...
Coulthard, S.A., Hogarth, L.A., Little, M.A., Matheson, E., Redfern, C.P.F., Minto, C.L.J., Hall, A.G.   +13 more
openaire   +3 more sources

The Clinical Impact of Thiopurine Methyltransferase Polymorphisms on Thiopurine Treatment

Nucleosides, Nucleotides and Nucleic Acids, 2004
Acute lymphoblastic leukaemia (ALL) is the most common malignancy of childhood. Although current treatment results in long term survival in over 70% of cases there is evidence that as many as 50% could have been cured using a less complex regimen with a lower incidence of long term side effects.
S A, Coulthard, E C, Matheson, A G, Hall, L A, Hogarth   +3 more
openaire   +2 more sources

Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives

Journal of Crohn's and Colitis, 2018
Thiopurines, available as azathioprine, mercaptopurine and thioguanine, are immunomodulating agents primarily used to maintain corticosteroid-free remission in patients with inflammatory bowel disease. To provide a state-of-the-art overview of thiopurine
Jean Fred Colombel, Nanne de Boer, Jeremy Sanderson   +2 more
exaly   +2 more sources

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

Lancet, The, 2009
International audienceBACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. METHODS:
Jacques Cosnes, Antoine Cortot, Xavier Hébuterne   +2 more
exaly   +2 more sources

Individualization of Thiopurine Therapy: Thiopurine S -Methyltransferase and Beyond

Pharmacogenomics, 2009
The metabolism of a given drug depends, not solely on a particular enzyme, but rather on a complex metabolic network. Thiopurine S-methyltransferase (TPMT) catalyzes the methylation, and thus deactivation, of 6-mercaptopurine, a thiopurine used in the treatment of acute lymphoblastic leukemia.
Natasa, Karas-Kuzelicki, Irena, Mlinaric-Rascan   +1 more
openaire   +2 more sources

Thiopurine Methyltransferase and Thiopurine Metabolite Testing in Patients with Inflammatory Bowel Disease who are Taking Thiopurine Drugs

Pharmacogenomics, 2009
Thiopurine methyltransferase genotyping and thiopurine metabolite testing has been established as an adjunct to monitoring patients taking thiopurine drugs. This special report describes the clinical implications for this type of testing for patients with inflammatory bowel disease who are taking thiopurine drugs.
Leslie J, Sheffield, Peter, Irving, Arun, Gupta, Keith, Byron, Finlay A, Macrae, Hazel, Phillimore, Mithilesh, Dronavalli, Rosemary, Rose, Peter, George, Trevor, Walmsley, Barbara, Dixon, Susan, Poole, Michael, Dooley, Miles, Sparrow   +13 more
openaire   +2 more sources

Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy

Therapeutic Drug Monitoring, 2004
Most medications exhibit wide interpatient variability in their efficacy and toxicity. For many medications, these interindividual differences result in part from polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, and/or drug targets (eg, receptors, enzymes).
openaire   +2 more sources

A practical guide to the use of thiopurines in oral medicine

Journal of Oral Pathology and Medicine, 2015
Thiopurines are widely used as first-line immunosuppressive therapies in the management of chronic inflammatory oral disease. However, despite over half a century of clinical experience, the evidence base for their use is limited.
Hullah, E. A., Sanderson, J. D., Marinaki, A. M., Blaker, P. A., Escudier, M. P.   +4 more
exaly   +2 more sources

Biology and Pharmacology of Thiopurines

Pediatric Hematology and Oncology, 1995
(1995). Biology and Pharmacology of Thiopurines. Pediatric Hematology and Oncology: Vol. 12, No. 5, pp. 511-519.
openaire   +2 more sources